Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALTS ALT5 Sigma	$7.21 +3.6%	$7.98	$1.55 ▼ $10.95	$155.81M	2.17	1.04 million shs	16.29 million shs
FATE Fate Therapeutics	$1.07 -5.3%	$1.18	$0.66 ▼ $4.20	$122.62M	2.24	2.06 million shs	1.68 million shs
FTLF FitLife Brands	$16.15 -0.4%	$13.65	$9.83 ▼ $17.75	$151.65M	0.79	20,529 shs	15,648 shs
KLTO Klotho Neurosciences	$0.78 -1.9%	$1.21	$0.11 ▼ $3.91	$35.87M	10.9	17.90 million shs	1.04 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALTS ALT5 Sigma	+16.78%	+2.81%	0.00%	+11.36%	+276.22%
FATE Fate Therapeutics	+20.69%	+8.65%	-0.88%	+11.88%	-66.17%
FTLF FitLife Brands	-3.34%	+8.57%	+23.91%	+12.17%	+1.37%
KLTO Klotho Neurosciences	-1.64%	-16.50%	-36.47%	+303.10%	+79,409,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALTS ALT5 Sigma	0.617 of 5 stars	0.0	4.0	0.0	0.0	3.2	0.0	0.0
FATE Fate Therapeutics	4.1586 of 5 stars	3.1	2.0	0.0	4.7	3.0	2.5	0.6
FTLF FitLife Brands	4.0552 of 5 stars	3.7	3.0	0.0	0.0	2.5	1.7	3.1
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALTS ALT5 Sigma	0.00	N/A	N/A	N/A
FATE Fate Therapeutics	2.13	Hold	$3.58	230.26% Upside
FTLF FitLife Brands	3.33	Buy	$20.50	26.19% Upside
KLTO Klotho Neurosciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KLTO, FTLF, ALTS, and FATE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $2.50
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALTS ALT5 Sigma	$12.53M	12.34	N/A	N/A	$0.49 per share	14.60
FATE Fate Therapeutics	$13.63M	9.12	N/A	N/A	$2.80 per share	0.39
FTLF FitLife Brands	$64.47M	2.37	$0.98 per share	16.56	$3.93 per share	4.13
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALTS ALT5 Sigma	-$6.24M	N/A	0.00	∞	N/A	-38.58%	-113.79%	-8.96%	N/A
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-2,025.05%	-48.52%	-35.25%	N/A
FTLF FitLife Brands	$8.98M	$0.84	19.34	14.77	N/A	13.85%	25.59%	15.26%	N/A
KLTO Klotho Neurosciences	-$6.15M	-$0.36	N/A	∞	N/A	N/A	-1,779.01%	-275.01%	8/18/2025 (Estimated)

Latest KLTO, FTLF, ALTS, and FATE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FTLF FitLife Brands	$0.18	$0.18	N/A	$0.18	N/A	N/A
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$1.16 million	$1.91 million
5/15/2025	Q1 2025	FTLF FitLife Brands	$0.24	$0.20	-$0.04	$0.20	N/A	N/A
5/15/2025	Q1 2025	KLTO Klotho Neurosciences	N/A	-$0.08	N/A	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALTS ALT5 Sigma	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
KLTO Klotho Neurosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALTS ALT5 Sigma	1.26	0.83	0.83
FATE Fate Therapeutics	N/A	8.81	8.81
FTLF FitLife Brands	0.19	1.64	0.72
KLTO Klotho Neurosciences	N/A	0.29	0.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALTS ALT5 Sigma	6.27%
FATE Fate Therapeutics	97.54%
FTLF FitLife Brands	2.32%
KLTO Klotho Neurosciences	20.07%

Insider Ownership

Company	Insider Ownership
ALTS ALT5 Sigma	4.90%
FATE Fate Therapeutics	5.51%
FTLF FitLife Brands	61.40%
KLTO Klotho Neurosciences	26.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALTS ALT5 Sigma	170	21.61 million	19.16 million	N/A
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
FTLF FitLife Brands	20	9.39 million	3.63 million	Not Optionable
KLTO Klotho Neurosciences	N/A	46.05 million	33.76 million	N/A

KLTO, FTLF, ALTS, and FATE Headlines

Recent News About These Companies

Klotho Neurosciences Delays Quarterly Report Filing

1 hour ago | msn.com

Klotho Neurosciences begins manufacturing of KLTO-202 product candidate using AAVnerGene's platform technology

August 13 at 2:24 AM | pharmabiz.comP

Klotho Neurosciences signs KLTO-202 manufacturing, development agreement

August 12 at 3:22 PM | msn.com

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using ...

August 12 at 7:07 AM | gurufocus.com

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using ...

August 12 at 7:07 AM | gurufocus.com

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology

August 12 at 6:00 AM | prnewswire.com

Klotho Neurosciences, Inc. Common Stock (KLTO) Institutional Holdings

August 11 at 10:53 AM | nasdaq.com

UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology | KLTO ...

July 25, 2025 | gurufocus.com

UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

July 25, 2025 | prnewswire.com

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

July 24, 2025 | prnewswire.com

Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets

July 22, 2025 | prnewswire.com

Klotho Neurosciences regains full compliance with Nasdaq listing standards

July 16, 2025 | msn.com

Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules

July 16, 2025 | prnewswire.com

New UAB-developed gene therapy for ALS receives orphan drug designation

July 15, 2025 | news-medical.netN

ALS gene therapy candidate KLTO‑202 wins orphan drug status

July 15, 2025 | alsnewstoday.comA

US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis

July 12, 2025 | pharmabiz.comP

Klotho Neurosciences stock soars after FDA grants orphan drug status ...

July 11, 2025 | uk.investing.com

KLTO: Klotho Neurosciences, Inc. Common Stock Stock Price, Quote ...

July 11, 2025 | fxempire.comF

Klotho Neurosciences stock soars after FDA grants orphan drug status for ALS

July 10, 2025 | ca.investing.com

Klotho Neurosciences Shares Jump as FDA Grants Orphan Drug Status for ALS Therapy

July 10, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLTO, FTLF, ALTS, and FATE Company Descriptions

ALT5 Sigma NASDAQ:ALTS

$7.21 +0.25 (+3.59%)

Closing price 04:00 PM Eastern

Extended Trading

$7.22 +0.01 (+0.21%)

As of 05:43 PM Eastern

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Fate Therapeutics NASDAQ:FATE

$1.07 -0.06 (-5.31%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 +0.00 (+0.47%)

As of 05:41 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FitLife Brands NASDAQ:FTLF

$16.15 -0.07 (-0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$16.24 +0.10 (+0.59%)

As of 04:20 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Klotho Neurosciences NASDAQ:KLTO

$0.78 -0.02 (-1.90%)

As of 04:00 PM Eastern

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time